Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

An integrated prediction model of recurrence in endometrial endometrioid cancers.

Miller MD, Salinas EA, Newtson AM, Sharma D, Keeney ME, Warrier A, Smith BJ, Bender DP, Goodheart MJ, Thiel KW, Devor EJ, Leslie KK, Gonzalez-Bosquet J.

Cancer Manag Res. 2019 Jun 6;11:5301-5315. doi: 10.2147/CMAR.S202628. eCollection 2019.

2.

Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer.

McDonald ME, Salinas EA, Devor EJ, Newtson AM, Thiel KW, Goodheart MJ, Bender DP, Smith BJ, Leslie KK, Gonzalez-Bosquet J.

Int J Mol Sci. 2019 Mar 7;20(5). pii: E1175. doi: 10.3390/ijms20051175.

3.

A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables.

Salinas EA, Miller MD, Newtson AM, Sharma D, McDonald ME, Keeney ME, Smith BJ, Bender DP, Goodheart MJ, Thiel KW, Devor EJ, Leslie KK, Gonzalez Bosquet J.

Int J Mol Sci. 2019 Mar 9;20(5). pii: E1205. doi: 10.3390/ijms20051205.

4.

Population Substructure Has Implications in Validating Next-Generation Cancer Genomics Studies with TCGA.

Miller MD, Devor EJ, Salinas EA, Newtson AM, Goodheart MJ, Leslie KK, Gonzalez-Bosquet J.

Int J Mol Sci. 2019 Mar 8;20(5). pii: E1192. doi: 10.3390/ijms20051192.

5.

Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer.

Armer JS, Clevenger L, Davis LZ, Cuneo M, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Sood AK, Cole SW, Slavich GM, Lutgendorf SK.

Cancer. 2018 Aug;124(16):3401-3408. doi: 10.1002/cncr.31570. Epub 2018 Jun 15.

6.

Alterations of Vascular Endothelial Growth Factor A Expression and Microvessel Density Associated With Polypropylene Vaginal Mesh.

Kowalski JT, Goodheart MJ, Genadry R, Bhattarai A, Bradley CS.

Female Pelvic Med Reconstr Surg. 2018 Apr 20. doi: 10.1097/SPV.0000000000000593. [Epub ahead of print]

PMID:
29683889
7.

Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.

Hamilton CA, Miller A, Casablanca Y, Horowitz NS, Rungruang B, Krivak TC, Richard SD, Rodriguez N, Birrer MJ, Backes FJ, Geller MA, Quinn M, Goodheart MJ, Mutch DG, Kavanagh JJ, Maxwell GL, Bookman MA.

Gynecol Oncol. 2018 Feb;148(2):275-280. doi: 10.1016/j.ygyno.2017.11.018. Epub 2017 Nov 28.

8.

Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma.

Lutgendorf SK, Thaker PH, Arevalo JM, Goodheart MJ, Slavich GM, Sood AK, Cole SW.

Cancer. 2018 Feb 1;124(3):580-586. doi: 10.1002/cncr.31078. Epub 2017 Nov 7.

9.

Uterine Clostridium perfringens infection related to gynecologic malignancy.

Kremer KM, McDonald ME, Goodheart MJ.

Gynecol Oncol Rep. 2017 Sep 21;22:55-57. doi: 10.1016/j.gore.2017.09.006. eCollection 2017 Nov.

10.

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.

Kristeleit R, Davidenko I, Shirinkin V, El-Khouly F, Bondarenko I, Goodheart MJ, Gorbunova V, Penning CA, Shi JG, Liu X, Newton RC, Zhao Y, Maleski J, Leopold L, Schilder RJ.

Gynecol Oncol. 2017 Sep;146(3):484-490. doi: 10.1016/j.ygyno.2017.07.005. Epub 2017 Jul 8.

PMID:
28698009
11.

Changes in spiritual well-being and psychological outcomes in ovarian cancer survivors.

Davis LZ, Cuneo M, Thaker PH, Goodheart MJ, Bender D, Lutgendorf SK.

Psychooncology. 2018 Feb;27(2):477-483. doi: 10.1002/pon.4485. Epub 2017 Aug 4.

12.

Placenta-Specific Protein 1 Expression in Human Papillomavirus 16/18-Positive Cervical Cancers Is Associated With Tumor Histology.

Devor EJ, Reyes HD, Gonzalez-Bosquet J, Warrier A, Kenzie SA, Ibik NV, Miller MD, Schickling BM, Goodheart MJ, Thiel KW, Leslie KK.

Int J Gynecol Cancer. 2017 May;27(4):784-790. doi: 10.1097/IGC.0000000000000957.

13.

p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers.

Devor EJ, Gonzalez-Bosquet J, Warrier A, Reyes HD, Ibik NV, Schickling BM, Newtson A, Goodheart MJ, Leslie KK.

Int J Oncol. 2017 May;50(5):1721-1728. doi: 10.3892/ijo.2017.3931. Epub 2017 Mar 23.

14.

Use of hyperbaric oxygen therapy and PEGylated carboxyhemoglobin bovine in a Jehovah's Witness with life-threatening anemia following postpartum hemorrhage.

Thenuwara K, Thomas J, Ibsen M, Ituk U, Choi K, Nickel E, Goodheart MJ.

Int J Obstet Anesth. 2017 Feb;29:73-80. doi: 10.1016/j.ijoa.2016.10.006. Epub 2016 Oct 24.

PMID:
27890467
15.

What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.

Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD.

Cancer. 2017 May 15;123(6):985-993. doi: 10.1002/cncr.30414. Epub 2016 Nov 16.

16.

Prediction of chemo-response in serous ovarian cancer.

Gonzalez Bosquet J, Newtson AM, Chung RK, Thiel KW, Ginader T, Goodheart MJ, Leslie KK, Smith BJ.

Mol Cancer. 2016 Oct 19;15(1):66.

17.

Sox2 and Lef-1 interact with Pitx2 to regulate incisor development and stem cell renewal.

Sun Z, Yu W, Sanz Navarro M, Sweat M, Eliason S, Sharp T, Liu H, Seidel K, Zhang L, Moreno M, Lynch T, Holton NE, Rogers L, Neff T, Goodheart MJ, Michon F, Klein OD, Chai Y, Dupuy A, Engelhardt JF, Chen Z, Amendt BA.

Development. 2016 Nov 15;143(22):4115-4126. Epub 2016 Sep 22.

18.

Bladder cancer will grow anywhere: report of a urothelial carcinoma drop metastasis to the vagina and literature review.

Uhlman MA, Bevill MD, Goodheart MJ, Brown JA, O'Donnell MA.

Can J Urol. 2016 Aug;23(4):8379-81.

PMID:
27544563
19.

Malignant struma ovarii with insular carcinoma: A case report and literature review.

Williams H, Salinas E, Savage E, Samuelson M, Goodheart MJ.

Gynecol Oncol Rep. 2016 Aug 22;18:1-3. doi: 10.1016/j.gore.2016.08.003. eCollection 2016 Nov.

20.

Wnt Signaling Regulates Airway Epithelial Stem Cells in Adult Murine Submucosal Glands.

Lynch TJ, Anderson PJ, Xie W, Crooke AK, Liu X, Tyler SR, Luo M, Kusner DM, Zhang Y, Neff T, Burnette DC, Walters KS, Goodheart MJ, Parekh KR, Engelhardt JF.

Stem Cells. 2016 Nov;34(11):2758-2771. doi: 10.1002/stem.2443. Epub 2016 Jul 11.

21.

Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations.

Dai D, Thiel KW, Salinas EA, Goodheart MJ, Leslie KK, Gonzalez Bosquet J.

Gynecol Oncol. 2016 Jul;142(1):150-157. doi: 10.1016/j.ygyno.2016.05.012. Epub 2016 May 16.

22.

SSRI use and clinical outcomes in epithelial ovarian cancer.

Christensen DK, Armaiz-Pena GN, Ramirez E, Matsuo K, Zimmerman B, Zand B, Shinn E, Goodheart MJ, Bender D, Thaker PH, Ahmed A, Penedo FJ, DeGeest K, Mendez L, Domann F, Sood AK, Lutgendorf SK.

Oncotarget. 2016 May 31;7(22):33179-91. doi: 10.18632/oncotarget.8891.

23.

Conditional deletion of Sox17 reveals complex effects on uterine adenogenesis and function.

Guimarães-Young A, Neff T, Dupuy AJ, Goodheart MJ.

Dev Biol. 2016 Jun 15;414(2):219-27. doi: 10.1016/j.ydbio.2016.04.010. Epub 2016 Apr 19.

24.

Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182.

Devor EJ, Schickling BM, Reyes HD, Warrier A, Lindsay B, Goodheart MJ, Santillan DA, Leslie KK.

Oncol Rep. 2016 Apr;35(4):2461-5. doi: 10.3892/or.2016.4605. Epub 2016 Feb 1.

25.

Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.

Reyes HD, Carlson MJ, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Yang S, Stephan JM, Savage EC, Dai D, Goodheart MJ, Leslie KK.

Gynecol Oncol. 2016 Jan;140(1):152-60. doi: 10.1016/j.ygyno.2015.10.023. Epub 2015 Oct 30.

26.

Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer.

Davis LZ, Slavich GM, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Farley DM, Markon KE, Penedo FJ, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK.

Cancer. 2015 Oct 1;121(19):3543-50. doi: 10.1002/cncr.29516. Epub 2015 Jun 10.

27.

The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients.

Hansen J, Stephan JM, Freesmeier M, Bender D, Button A, Goodheart MJ.

Gynecol Oncol. 2015 Jul;138(1):154-8. doi: 10.1016/j.ygyno.2015.04.040. Epub 2015 May 6.

PMID:
25958318
28.

CGRP induction in cystic fibrosis airways alters the submucosal gland progenitor cell niche in mice.

Xie W, Fisher JT, Lynch TJ, Luo M, Evans TI, Neff TL, Zhou W, Zhang Y, Ou Y, Bunnett NW, Russo AF, Goodheart MJ, Parekh KR, Liu X, Engelhardt JF.

J Clin Invest. 2015 May;125(5):2179. doi: 10.1172/JCI82138. Epub 2015 May 1. No abstract available.

29.

Diurnal cortisol and survival in epithelial ovarian cancer.

Schrepf A, Thaker PH, Goodheart MJ, Bender D, Slavich GM, Dahmoush L, Penedo F, DeGeest K, Mendez L, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK.

Psychoneuroendocrinology. 2015 Mar;53:256-67. doi: 10.1016/j.psyneuen.2015.01.010. Epub 2015 Jan 20.

30.

Robotic surgery in supermorbidly obese patients with endometrial cancer.

Stephan JM, Goodheart MJ, McDonald M, Hansen J, Reyes HD, Button A, Bender D.

Am J Obstet Gynecol. 2015 Jul;213(1):49.e1-49.e8. doi: 10.1016/j.ajog.2015.01.052. Epub 2015 Jan 30.

PMID:
25644437
31.

TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.

Brachova P, Mueting SR, Carlson MJ, Goodheart MJ, Button AM, Mott SL, Dai D, Thiel KW, Devor EJ, Leslie KK.

Int J Oncol. 2015 Feb;46(2):607-18. doi: 10.3892/ijo.2014.2747. Epub 2014 Nov 11.

32.

MicroRNA-26b represses colon cancer cell proliferation by inhibiting lymphoid enhancer factor 1 expression.

Zhang Z, Kim K, Li X, Moreno M, Sharp T, Goodheart MJ, Safe S, Dupuy AJ, Amendt BA.

Mol Cancer Ther. 2014 Jul;13(7):1942-51. doi: 10.1158/1535-7163.MCT-13-1000. Epub 2014 Apr 30.

33.

Placenta-specific protein 1: a potential key to many oncofetal-placental OB/GYN research questions.

Devor EJ, Reyes HD, Santillan DA, Santillan MK, Onukwugha C, Goodheart MJ, Leslie KK.

Obstet Gynecol Int. 2014;2014:678984. doi: 10.1155/2014/678984. Epub 2014 Mar 17.

34.

Intra-operative frozen section results reliably predict final pathology in endometrial cancer.

Stephan JM, Hansen J, Samuelson M, McDonald M, Chin Y, Bender D, Reyes HD, Button A, Goodheart MJ.

Gynecol Oncol. 2014 Jun;133(3):499-505. doi: 10.1016/j.ygyno.2014.03.569. Epub 2014 Apr 1.

PMID:
24699308
35.

Sox2 modulates Lef-1 expression during airway submucosal gland development.

Xie W, Lynch TJ, Liu X, Tyler SR, Yu S, Zhou X, Luo M, Kusner DM, Sun X, Yi Y, Zhang Y, Goodheart MJ, Parekh KR, Wells JM, Xue HH, Pevny LH, Engelhardt JF.

Am J Physiol Lung Cell Mol Physiol. 2014 Apr 1;306(7):L645-60. doi: 10.1152/ajplung.00157.2013. Epub 2014 Jan 31.

36.

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Martin LP, Sill M, Shahin MS, Powell M, DiSilvestro P, Landrum LM, Gaillard SL, Goodheart MJ, Hoffman J, Schilder RJ.

Gynecol Oncol. 2014 Mar;132(3):526-30. doi: 10.1016/j.ygyno.2013.12.018. Epub 2013 Dec 18.

37.

Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer.

Nadkarni NJ, Geest KD, Neff T, Young BD, Bender DP, Ahmed A, Smith BJ, Button A, Goodheart MJ.

Cancer Lett. 2013 Apr 30;331(1):99-104. doi: 10.1016/j.canlet.2012.12.016. Epub 2012 Dec 23.

PMID:
23268330
38.

Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma.

Devor EJ, DE Mik JN, Ramachandran S, Goodheart MJ, Leslie KK.

Exp Ther Med. 2012 Apr;3(4):677-682. Epub 2012 Jan 25.

39.

Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability.

Schrepf A, Clevenger L, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Penedo F, Lucci JA 3rd, Ganjei-Azar P, Mendez L, Markon K, Lubaroff DM, Thaker PH, Slavich GM, Sood AK, Lutgendorf SK.

Brain Behav Immun. 2013 Mar;30 Suppl:S126-34. doi: 10.1016/j.bbi.2012.07.022. Epub 2012 Aug 5.

40.

Social influences on clinical outcomes of patients with ovarian cancer.

Lutgendorf SK, De Geest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Zimmerman MB, Penedo FJ, Lucci JA 3rd, Ganjei-Azar P, Thaker PH, Mendez L, Lubaroff DM, Slavich GM, Cole SW, Sood AK.

J Clin Oncol. 2012 Aug 10;30(23):2885-90. doi: 10.1200/JCO.2011.39.4411. Epub 2012 Jul 16.

41.

The role of LEF1 in endometrial gland formation and carcinogenesis.

Shelton DN, Fornalik H, Neff T, Park SY, Bender D, DeGeest K, Liu X, Xie W, Meyerholz DK, Engelhardt JF, Goodheart MJ.

PLoS One. 2012;7(7):e40312. doi: 10.1371/journal.pone.0040312. Epub 2012 Jul 6.

42.

Endometrial cancer.

Leslie KK, Thiel KW, Goodheart MJ, De Geest K, Jia Y, Yang S.

Obstet Gynecol Clin North Am. 2012 Jun;39(2):255-68. doi: 10.1016/j.ogc.2012.04.001.

43.

Intraoperative autologous blood transfusion use during radical hysterectomy for cervical cancer: long-term follow-up of a prospective trial.

Engle DB, Connor JP, Morris PC, Bender DP, De Geest K, Ahmed A, Goodheart MJ.

Arch Gynecol Obstet. 2012 Sep;286(3):717-21. doi: 10.1007/s00404-012-2351-1. Epub 2012 May 9.

PMID:
22569711
44.

Sleep disturbance, cytokines, and fatigue in women with ovarian cancer.

Clevenger L, Schrepf A, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Penedo F, Lubaroff DM, Sood AK, Lutgendorf SK.

Brain Behav Immun. 2012 Oct;26(7):1037-44. doi: 10.1016/j.bbi.2012.04.003. Epub 2012 Apr 21.

45.

Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers.

Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR.

Curr Oncol Rep. 2012 Aug;14(4):277-84. doi: 10.1007/s11912-012-0238-8. Review.

PMID:
22532266
46.

CGRP induction in cystic fibrosis airways alters the submucosal gland progenitor cell niche in mice.

Xie W, Fisher JT, Lynch TJ, Luo M, Evans TI, Neff TL, Zhou W, Zhang Y, Ou Y, Bunnett NW, Russo AF, Goodheart MJ, Parekh KR, Liu X, Engelhardt JF.

J Clin Invest. 2011 Aug;121(8):3144-58. doi: 10.1172/JCI41857. Epub 2011 Jul 18. Erratum in: J Clin Invest. 2015 May;125(5):2179.

47.

microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs.

Devor EJ, Hovey AM, Goodheart MJ, Ramachandran S, Leslie KK.

Oncol Rep. 2011 Oct;26(4):995-1002. doi: 10.3892/or.2011.1372. Epub 2011 Jul 1.

48.

A single-institution evaluation of factors important in fallopian tube carcinoma recurrence and survival.

Shamshirsaz AA, Buekers T, Degeest K, Bender D, Zamba G, Goodheart MJ.

Int J Gynecol Cancer. 2011 Oct;21(7):1232-40. doi: 10.1097/IGC.0b013e318220fc46.

PMID:
21720254
49.

Sox17 modulates Wnt3A/beta-catenin-mediated transcriptional activation of the Lef-1 promoter.

Liu X, Luo M, Xie W, Wells JM, Goodheart MJ, Engelhardt JF.

Am J Physiol Lung Cell Mol Physiol. 2010 Nov;299(5):L694-710. doi: 10.1152/ajplung.00140.2010. Epub 2010 Aug 27.

50.

Intestinal lymphangiectasia mimicking primary peritoneal carcinoma.

Steines JC, Larson JH, Wilkinson N, Kirby P, Goodheart MJ.

Am J Obstet Gynecol. 2010 Oct;203(4):e9-e11. doi: 10.1016/j.ajog.2010.07.009.

PMID:
20801422

Supplemental Content

Loading ...
Support Center